Hypertransaminasemia in patients with negative viral markers;Hipertransaminasemia en pacientes con negatividad de marcadores virales

Revista Espanola de Enfermedades Digestivas

Volumn 96, Issue 7, 2004, Pages 484-500

  Cuadrado, A ^a   Crespo, Javier ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CARBAMAZEPINE; CERULOPLASMIN; PHENOBARBITAL; THYROID HORMONE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL LIVER DISEASE; ALKALINE PHOSPHATASE BLOOD LEVEL; ALPHA 1 ANTITRYPSIN DEFICIENCY; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUTOIMMUNE HEPATITIS; CERULOPLASMIN BLOOD LEVEL; EOSINOPHILIA; FATTY LIVER; GENETIC ANALYSIS; HEMOCHROMATOSIS; HORMONE DETERMINATION; HUMAN; HYPERTHYROIDISM; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TOXICITY; NONALCOHOLIC FATTY LIVER; OBSTRUCTIVE JAUNDICE; PHENOTYPE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; RASH; SEX DIFFERENCE; VIRUS HEPATITIS; WILSON DISEASE;

EID: 4544280476     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082004000700006     Document Type: Article

References (34)

1. Dufour DR, Lott JA, Nolte FS, et al. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000; 46: 2050-68.
2. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2002; 342: 1266-71.
3. Davern II TJ, Scharschmidt BF. Biochemical liver tests. En: Feldman M, Scharchmidt BF, Sleisenger MH, eds. Gastrointestinal and Liver Disease. Philadelphia: W.B. Saunders, 1998. p. 1112-22.
4. Craxi A, Almasio P. Diagnostic approach to liver enzyme elevation. J Hepatol 1996; 25 (Supl. 1): 47-51.
5. Stewart SF, Day CP. The manegement of alcoholic liver disease. J Hepatol 2003; 38: S2-S13.
6. Maher JJ. Alcoholic liver disease. En: Feldman M, Scharchmidt BF, Sleisenger MH, eds. Gastrointestinal and Liver Disease. Philadelphia: W.B. Saunders, 1998. p. 1199-214.
7. Maddrey WC, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193-9.
8. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-71.
9. Vargas V, Ortiz M. Modelos pronósticos en la cirrosis hepática. El modelo MELD. Gastroenterol Hepatol 2003; 26 (4): 257-9.
10. Angulo P. Nonalcoholic fatty liver disease. N Eng J Med 2002; 346 (16): 1221-31.
11. Daniel S, Ben-Menachem T, Vasudevan G, et al. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999; 94: 3010-4.
12. García-Monzón C. Esteatohepatitis no alcohólica. Gastroenterología y Hepatología 2001; 24 (8): 395-402.
13. Rodríguez C, Martín L. Estudio del paciente con elevación de transaminasas. GH continuada 2002; 1: 345-8.
14. Czaja AJ, Freese DK. Diagnosis and treatment of autoinmune hepatitis. Hepatology 2002; 36(2): 479-93.
15. Lewis JH. Drug-induced liver disease. Med Clin North Am 2000; 84: 1275-311.
16. Dossing M, Sonne J. Drug-induced hepatic disorders. Incidence, management and avoidance. Drug Saf 1993; 9: 441-9.
17. Larrey D. Drug-induced liver diseases. J Hepatol 2000; 32 (Supl. 1): 77-8.
18. Fernández-Bermejo M, Robledo P, Mateos JM. Hepatotoxicidad por fármacos: diagnóstico y tratamiento. Gastroenterología Práctica 2003; 12: 4-6.
19. Andrade RJ, Lucena MI, García-Escaño, et al. Hepatotoxicity in patients with cirrhosis, an often unrecognized problem. Lessons from a fatal case related with amoxicillin/clavulanic acid. Dig Dis Sci 2001; 46: 1416-9.
20. Lucena MI, Camargo R, Andrade RJ, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33: 123-30.
21. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001; 33 (5): 1321-8.
22. Harrison SA, Bacon BR. Hereditary hemochromatosis: update for 2003. J Hepatol 2003; 38: S14-S23.
23. Bacon BR. Hemochromatosis: diagnosis and management. Gastroenterology 2001; 120: 718-25.
24. Pardo A, Quintero E. Hemocromatosis hereditaria: diagnóstico y tratamiento. Gastroenterología Prá ctica 2002; 11 (3): 32-6.
25. Pérez-Aguilar F. Enfermedad de Wilson: consideraciones fisiopatológicas, clínicas y terapéuticas. Gastroenterol Hepatol 2003; 26 (1): 42-51.
26. Cosme A, Ojeda E, Torrado J, et al. Alteraciones hepáticas por déficit de alfa-l-antitripsina en adultos. Estudio de 5 pacientes y análisis de los casos publicados en la bibliografía española. Gastroenterol Hepatol 2002; 26 (4): 251-6.
27. Moreno R, García-Buey L. Diagnóstico y tratamiento de las colangiopatías autoinmunes. Gastroenterol Hepatol 2003; 26 (Supl. 2): 11-5.
28. Heathcote EJ. Management of primary biliary cirrhosis. Hepatology 2000; 31 (4): 1005-13.
29. Lindgren S, Eriksson S. IgM in primary biliary corrhosis. Physicochemical and complement activating properties. J Lab Clin Med 1982; 99: 636-45.
30. Wiesner RM, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980; 79: 200-6.
31. Jorge AD, Jorge OA. Colangitis esclerosante primaria. Revis Gastroenterol 2002; 4: 196-218.
32. Vidrich A, Lee J, James E, et al. Segregation of pANCA antigenic recognition by Dnase treatment of neutrophils: ulcerative colitis, type 1 autoinmune hepatitis and primary sclerosin cholangitis. J Clin Inmunol 1995; 15: 239-9.
33. Volta U, De Franceschi L, Lari F, et al. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet 1998; 352: 26-9.
34. Bardella MT, Cecchi M, Conte D, et al. Chronic unexplained hypertransaminasemia may be caused by occult celiac disease. Hepatology 1999; 29: 654-7.